A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination with Paclitaxel in Patients with Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African Ancestry
Study of Combination Drug in Patients with Advanced Triple Negative Breast Cancer (TNBC)
Sponsor: Calithera Biosciences Inc.
Enrolling: Female Patients Only
IRB Number: AAAR2902
U.S. Govt. ID: NCT03057600
Contact: Kevin Kalinsky, MD, MS: 212-305-1945 / kk2693@cumc.columbia.edu
Additional Study Information: The purpose of this trial is to determine whether the study drug, CX-839, reduces tumor size in patients with metastatic triple negative breast cancer when it is used in combination with the standard breast cancer treatment. CX-839 blocks the activity of a certain molecule that is overproduced by some cancer cells.
This study is closed
Investigator
Kevin Kalinsky, MD, MS
Do You Qualify?
Are you a woman who is 18 years of age or older? Yes No
Have you been diagnosed with metastatic breast cancer? Yes No
You may not be pregnant or become pregnant while on this trial. Are you willing to comply? Yes No
Do you have a life expectancy of at least 3 months? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Kevin Kalinsky, MD, MS
kk2693@cumc.columbia.edu
212-305-1945
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE